Top Page
Duality Biotherapeutics, Inc.
(9606)
Duality Biotherapeutics, Inc. (9606) vs. iShares MSCI Hong Kong ETF (EWH)
Duality Biotherapeutics, Inc. Business Overview & Revenue Model
Duality Biotherapeutics, Inc. Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Duality Biotherapeutics, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | 10.28B | 10.99 | 0.00% | 4.06% | 2.32% | -14.41% | |
69 Neutral | 11.27B | 235.71 | 2.56% | ― | 0.00% | 0.00% | |
66 Neutral | 7.85B | 21.09 | 12.91% | 2.29% | 16.41% | 32.97% | |
57 Neutral | 1.61B | -12.49 | -9.03% | ― | -30.60% | 28.61% | |
54 Neutral | 13.54B | 20.78 | 2.23% | ― | 59.70% | 239.97% | |
52 Neutral | HK$34.95B | ― | ― | ― | ― | ||
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Duality Biotherapeutics, Inc. Corporate Events
Duality Biotherapeutics, Inc., a company incorporated in the Cayman Islands, has announced its inclusion as a constituent of the Hang Seng Composite Index and as part of the eligible stock list for the Southbound Trading Link of the Shanghai-Hong Kong Stock Connect. This development signifies strong market recognition of the company’s performance and value, potentially expanding its investor base and increasing trading liquidity by allowing mainland Chinese investors to invest directly in its shares.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$367.06 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
Duality Biotherapeutics, Inc. announced that its Phase III clinical trial for DB-1303/BNT323 in HER2-positive unresectable or metastatic breast cancer patients met its primary endpoint of progression-free survival. This achievement marks a significant step towards the potential approval of DB-1303/BNT323, as the company plans to discuss a Biologics License Application with China’s National Medical Products Administration. The drug, developed in partnership with BioNTech SE, has shown promise across various cancer types and has received Fast Track and Breakthrough Therapy Designations from the FDA and NMPA, highlighting its potential impact on cancer treatment options.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$367.06 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
Duality Biotherapeutics, Inc. announced its interim results for the first half of 2025, highlighting a 22.9% increase in revenue compared to the same period in 2024, despite a significant loss for the period. The company has made substantial progress in its pipeline development, including the FDA’s Fast Track Designation for its HER3-targeting ADC DB-1310 and the initiation of a Phase 1/2 clinical study for DB-1418/AVZO-1418. These advancements, alongside promising clinical trial data presented at major oncology conferences, underscore Duality’s commitment to innovation in cancer treatment and its potential impact on the biotherapeutics industry.
The most recent analyst rating on (HK:9606) stock is a Hold with a HK$344.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
Duality Biotherapeutics, Inc. has announced a board meeting scheduled for August 26, 2025, to consider and approve the company’s unaudited interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
Duality Biotherapeutics, Inc. has announced that its key product, DB-1310, an antibody-drug conjugate targeting HER3, has received Fast Track Designation from the U.S. FDA. This designation is intended to expedite the development and review of drugs that treat serious conditions and address unmet medical needs. The designation for DB-1310 is specifically for treating advanced non-squamous non-small cell lung cancer in patients with specific genetic mutations who have progressed after other treatments. This development could enhance Duality Biotherapeutics’ position in the ADC market and potentially provide a new treatment option for patients with limited alternatives.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
Duality Biotherapeutics, Inc. announced the successful passage of all proposed resolutions during its Annual General Meeting held on June 20, 2025. The resolutions included the adoption of the company’s audited financial statements for 2024, re-election of directors, re-appointment of auditors, and granting of mandates to the directors for share repurchase and issuance. These decisions reflect strong shareholder support and are expected to enhance the company’s governance and operational flexibility.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.